Cost effectiveness of enzyme immunoassay and immunoblot testing for the diagnosis of syphilis

International Journal of STD and AIDS

Volumn 19, Issue 6, 2008, Pages 393-399

  Chuck, Anderson ^b   Ohinmaa, Arto ^a,b   Tilley, Peter ^c   Singh, Ameeta ^d   Jacobs, Philip ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^d Provincial Health Office   (Canada)

Author keywords

Cost effectiveness analysis; Economics; Screening; Syphilis; Testing

Indexed keywords

ARTICLE; CANADA; COST EFFECTIVENESS ANALYSIS; ENZYME IMMUNOASSAY; FLUORESCENT TREPONEMA ANTIBODY TEST; HEALTH CARE COST; HUMAN; IMMUNOBLOTTING; PRIORITY JOURNAL; SYPHILIS; TREPONEMA PALLIDUM;

ANTIBODIES, BACTERIAL; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; SYPHILIS; SYPHILIS SERODIAGNOSIS; TREPONEMA PALLIDUM;

EID: 47949084764     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2007.007272     Document Type: Article

References (18)

1. Hagedorn HJ, Hagedorn AK, De Bosschere K, et al. Evaluation of INNO-LIA syphilis assay as a confirmatory test for syphilis. J Clin Microbiol 2002;40:973-8
2. Young H, Moyes A, Seagar L, et al. Novel recombinant-antigen enzyme immunoassay for serological diagnosis of syphilis. J Clin Microbiol 1998;36:913-7
3. Castro R, Prieto ES, Santo I, et al. Evaluation of an enzyme immunoassay technique for detection of antibodies against Treponema pallidum. J Clin Microbiol 2003;41:250-3
4. Young H, Moyes A, McMillan A, et al. Enzyme immunoassay for anti-treponemal IgG: screening or confirmatory test? J Clin Microbiol 1992;45:37-41
5. Ebel AL, Vanneste L, Cardinaels M, et al. Validation of the INNO-LIA Syphilis kit as a confirmatory assay for Treponema pallidum antibodies. J Clin Microbiol 2000;38:215-9
6. A Cost Effectiveness Analysis of Incorporating Enzyme Immunoassay (EIA) and Immunoblot (Inno-Lia) Testing for the Diagnosis of Syphilis in Alberta, Canada. 07 Aug 20; Seattle, WA: ISSTDR, 2007
7. Peeling RW, Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. Bull World Health Organ 2004;82:439-46
8. Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev 1995;8:1-21
9. Alberta Health and Wellness. Alberta Treatment Guidelines: Sexually Transmitted Infections in Adolescents and Adults. 2003. [http://www.health. gov.ab.ca/professionals/STDTreatment.pdf]
10. Alberta Health and Wellness. Alberta Union Contracts. 2006
11. Alberta Health and Wellness. Alternative Relations Plan. 2006. [http://www.health.alberta.ca/professionals/ARPabout.html]
12. Alberta Health and Wellness. Alberta Health Care Insurance Plan: Medical Price List. 2006. [http://www.health.alberta.ca/professionals/ SOMB_Procedure_List.pdf ]
13. Rosahn PD. Autopsy studies in syphilis. J Vener Dis Infect 1947;21:1-67
14. Chesson HW, Blanford JM, Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:11-9
15. Bateman DA, Phibbs CS, Joyce T, et al. The hospital cost of congenital syphilis. J Pediat 1997;130:752-8
16. Singh AE, Romanowski B. Syphilis: Review with emphasis on clinical, epidemiologic, and some biological features. Clin Microbiol Rev 1999;12:187-209
17. Briggs AH. Handling uncertainty in economic evaluation. In: Drummond MF, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. New York: Oxford University Press, 2001
18. Briggs A. Handling uncertainty in cost effectiveness models. PharmacoEconomics 2000;17:479-500